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INTRODUCTION 
 Tuberous sclerosis complex (TSC) is a genetic disorder known to have a multi-system, 
neurocutaneous clinical presentation with an estimated incidence of 1 per 6,000 to 10,000 live 
births (1). The characteristic findings of TSC are skin lesions, seizures, hamartomas in the 
brain, kidneys, and heart in addition to a spectrum of neuropsychiatric conditions. The clinical 
manifestations of TSC show inter- and intra-familial variable expressivity and have the 
potential to fluctuate in severity over an affected individual’s lifetime (2, 3).  The 
pathophysiology of TSC arises from a heterozygous pathogenic variant in the tumor 
suppressor genes TSC1 and TSC2 that encode the instructions for the proteins hamartin and 
tuberin, respectively (4, 5). Consequently, the amount of functional protein is reduced, but the 
other copy provides enough products to effectively regulate cell growth. A second somatic 
pathogenic variant in TSC1 or TSC2 can lead to insufficient production of hamartin or tuberin 
and causes uncontrolled cell growth and division, resulting in hamartomas across multiple 
organ systems (6, 7). The pathohysiology of other clinical features associated with TSC is less 
well-understood. 
 At the 2012 International TSC Consensus Conference, the Neuropsychiatry Panel 
expressed concern regarding the 70% treatment gap and lack of uniformity in terminology 
regarding the non-physical manifestations associated with TSC (8). The term “treatment gap” 
refers to the difference between the portion of the population in need of services compared to 
the portion of the population actually receiving appropriate services (9). The members of the 
2012 International TSC Consensus Conference showed support for the previously coined term, 
TAND, or TSC-Associated Neuropsychiatric Disorders, in order to collectively represent the 
various domains of neuropsychiatric manifestations within the continuum of TSC symptoms 
(8, 10).  In order to address the treatment gap, the TAND checklist was developed and later 
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validated to serve as a screening tool for clinicians.  The TAND checklist serves as a 
streamlined method to identify the concern for neuropsychiatric manifestations with the 
ultimate goal of prompt and precise diagnosis as well as effective management of symptoms 
(11, 12). Along with the development of the TAND checklist, the recommendation was made 
for all individuals with TSC to undergo annual neuropsychiatric screening (12). It has been 
previously determined that 90% of children and adults with TSC will experience symptoms 
associated with TAND at some point during their lifetime, but fewer than 20% them will ever 
receive an appropriate TAND assessment and/or treatment (12). The 70% treatment gap for 
neuropsychiatric conditions in the TSC community is similarly observed in global studies 
regarding utilization of mental health care treatment (13, 14). Poor physical health in addition 
to poor mental health can contribute to a lower quality of life. It is therefore important to 
address the TAND treatment gap in the TSC community and provide opportunities to improve 
quality of life through the utilization of mental health services.  
 Even though treatment for mental health conditions has been documented as effective, 
there remain significant attitudinal and structural barriers that individuals struggle to overcome 
to reach proper mental health care services (15, 16).  Structural barriers, such as treatment 
availability, geographical access, and financial capability, continue to be important hurdles to 
obtaining mental health treatment. Attitudinal barriers, such as the negative connotation and 
stigma associated with undergoing mental health treatment, are more frequently reported in 
comparison to structural barriers as the cause behind lack of initiating as well as continuing 
treatment (17, 18). Unfortunately, the consequences of stigma lead to symptom denial and 
delay in treatment. Through education of the general public as well as healthcare providers, a 
reduction in negative beliefs and stigma of mental illnesses can contribute to elimination of 
barriers toward mental health treatment. The purpose of our study is to provide clinicians and 
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members of the TSC community with a more intimate, first-hand look into the impact of 
neuropsychiatric manifestations of TSC. Through a multi-faceted survey, our study evaluated 
perception of disease severity, presence of anxiety and depression, as well as the barriers and 
utilization of mental health services among adults with a diagnosis of TSC.  
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MATERIAL AND METHODS 
 Our study used a cross-sectional, web-based approach to survey adults with TSC. The 
electronic survey was designed using the Qualtrics online software (Qualtrics, Provo, UT). The 
survey components and recruitment strategy were developed by the authors and approved by 
the University of Texas Health Science Center at Houston Institutional Review Board (HSC-
MS-17-0599).  Data collection was performed from November 2017 through February 2018. 
Each participant provided consent electronically before completing the 30-minute survey. All 
survey responses were anonymous. To compensate for their time, participants who completed 
the survey were given the opportunity to provide a valid mailing address to receive a $5.00 gift 
card. The survey responses were kept separately from the mailing addresses. 
Study sample 
 Participants were recruited via email through the Tuberous Sclerosis (TS) Alliance.  
The TS Alliance Adult Regional Coordinators sent the survey to their constituents a minimum 
of three times over the previously mentioned time frame. Additionally, the researchers 
approached eligible participants in the TSC clinic at University of Texas Health Science 
Center at Houston. If they agreed to participate, then they were given an iPad to use in clinic to 
complete the survey. The eligibility criteria for both electronic and clinical participants 
included having a diagnosis of TSC, being 18 years or older, as well as having the ability to 
independently complete a 30-minute electronic survey. Eligible participants were first directed 
to the consent page. Once electronic consent was obtained, participants proceeded with the 
survey. 
Survey components 
 The structure of the survey included questions to determine the participant’s clinical 
care setting, evaluate their perception of disease severity, measure levels of depression and 
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anxiety, as well as their use and perspectives on mental health care services. Demographic 
information including age, sex, ethnicity, years since TSC diagnosis, occupation, income, and 
type of insurance was collected for all participants. The survey design set out to assess the 
influence of a person’s perception of disease severity on mental health and utilization of 
mental health care services. 
 The standardized and validated measures used in the survey included the Brief-Illness 
Perceptions Questionnaire (Brief-IPQ), Beck Anxiety Inventory (BAI), and Beck Depression 
Inventory-II (BDI-II). The Brief- IPQ was designed to provide a quick assessment of illness 
perceptions through single item questions on a scale from 0 to 10 to assess the severity of eight 
different dimension (19). The dimensions included “perceived consequences of their illness, 
timeline, perceived personal control, treatment control, identity, concern about the illness, 
coherence of illness, and emotional representation” (19). Permission to use the Brief-IPQ was 
obtained from the original authors. The BAI is the most widely used diagnostic instrument to 
discriminate between anxious and non-anxious groups (20, 21). The tool consists of 21-self 
reported items that assess for common symptoms of anxiety that have occurred during the past 
week including “numbness, feeling hot, nervousness, unsteadiness, dizziness, heart racing, fear 
of losing control, feeling scared, difficulty breathing, feeling faint, inability to relax and 
discomfort in the abdomen.” Each item is answered on a Likert scale ranging from 0 to 3 and 
the total score of all the items indicates whether the respondent has a low, moderate, or severe 
level of anxiety (22). The Beck Depression Inventory-II, or BDI-II, is one of the more 
extensively used self-reported measures for depression (23). It is comprised of 21-self reported 
items with a Likert scale ranging from 0 to 3. The Beck Depression Inventory-II (BDI-II) is a 
21-item, self-rated scale that evaluates key symptoms of depression having occurred during the 
past two weeks including “sadness, pessimism, past failure, loss of pleasure, guilty feelings, 
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punishment feelings, self-dislike, self-criticalness, suicidal thoughts or wishes, crying, 
agitation, loss of interest in activities, indecisiveness, worthlessness, loss of energy, change in 
sleeping pattern, irritability, changes in appetite, difficulty in concentration, tiredness, and loss 
of interest in sex” (23, 24). The total score indicates the presence as well as the severity of the 
depression in the respondent. Permission to use and reproduce both the BAI and BDI-II was 
obtained through Pearson Education. 
Statistical analysis 
 All data was extracted from Qualtrics and analysis was performed using Stata (v. 14, 
College Station, TX).  Categorical variables were described using frequencies (with 
percentages).  Medians (with interquartile range, IQR) and means (with standard deviation, sd) 
were used to describe continuous data that was not normally and normally distributed, 
respectively.  Categorical variables were compared across groups using contingency tests 
(Fisher exact or Chi-square).  Distributions of continuous variables were compared across 
groups using a Mann-Whitney test (for comparisons between two groups) or a Kruskal-Wallis 
test with post-hoc Dunn's test (for comparisons between more than two groups). To analyze 
the impact of stigma and cost as a barrier to the utilization of mental health resources, values 
were assigned to each response with 5 representing strongly agree and 1 representing strongly 
disagree. Then, for each participant the response value for cost as a barrier was subtracted 
from their response value for is stigma a barrier, which assigned respondents an overall 
positive, negative, or zero response value. Spearman's correlation coefficients were utilized to 
assess relationships between BDI-II, BAI and Brief-IPQ scores. Statistical significance was 
assumed at a Type I error rate of 5%. 
 
 
7 
RESULTS 
Demographics and Clinical Experience  
 The data collection process and demographic information of the 71 participants is 
listed Table 1 and illustrated in Figure 1.  The average age of the study participants was 43.7 
years old (sd 13.2). The majority of respondents were Caucasian (88%, n = 62), female (73%, 
n = 52), and received their initial clinical diagnosis of TSC over 10 years ago (86%, n = 61). 
Of the 71 respondents, over a quarter (28%, n = 20) reported receiving a diagnosis of 
intellectual disability. In regards to clinical experience, 39% (n = 28) reported receiving care in 
a multidisciplinary setting, while 61% (n = 43) reported a non-multidisciplinary clinical care 
setting. In our study, a multidisciplinary clinical care setting was defined as seeing multiple 
doctors from different specialties in a single clinic visit. A non-multidisciplinary clinic was 
defined as seeing a single specialty or multiple specialties in independent clinic visits.  Out of 
the 43 individuals who reported receiving care in a non-multidisciplinary clinical setting, just 
over a quarter (28%, n = 12) reported not having any medical provider for their TSC diagnosis. 
From the 28 respondents who reported receiving care in a multidisciplinary clinic, the most 
frequently seen specialties were neurology and nephrology at 35% and 28%, respectively. The 
least commonly seen specialties in a multidisciplinary setting were psychiatry and 
endocrinology at 2% each. The most frequently reported specialties seen in a non-
multidisciplinary setting (n = 31) were neurology and nephrology at 25% and 18%, 
respectively. The least commonly seen specialty in a non-multidisciplinary clinic setting was 
genetics at 2%.  Respondents who reported receiving care in a multidisciplinary setting also 
reported being seen by more physicians in the past year (median: 2; IQR: 1-3) compared to 
respondents receiving care in a non-multidisciplinary clinic (median: 1; IQR: 0-3) (p=0.007).  
Additionally, these same multidisciplinary clinic patients made significantly fewer clinic visits 
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in the last year (median: 1; IQR: 0-2) compared to the non-multidisciplinary clinic patients 
(median: 2; IQR: 1-4) (p=0.009).  
 
Figure 1: Breakdown of Survey Responses 
 
 
 
 
 
Completed Beck Depression Inventory-
II: 
n = 69 
Completed Beck Anxiety Inventory: 
n = 71 
Completed Demographics: 
n = 71 
Duplicated Surveys 
Didn’t have TSC 
Completed Demographic Information 
Only: 
n = 9 
Completed Clinical Experience: 
n = 71 
Completed Brief-Illness Perception 
Questionnaire: 
n = 69 
Completed Utilization of Mental Health 
Services: 
n = 69 
Total Number Surveys 
Returned: 
n = 80 
Figure 1 shows the breakdown of responses by highlighting the number of surveys 
returned, respondents who did not meet inclusion criteria, as well as the total sample 
size for each of the six components of the survey. 
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Table 1: Participant Demographics 
Age  Percent (%) 
Mean (SD)  43.7 (13.2) 
18-24 10% 
25-34 14% 
35-44 32% 
45-54 13% 
55 +  31% 
Years since TSC Diagnosis  
1-10 14% 
11-20 27% 
>20 59% 
Diagnosis of Intellectual Disability  
Yes 28% 
No 72% 
Sex  
Female 73% 
Male 25% 
Non-Binary 2% 
Race  
Asian 3% 
African American 1% 
Caucasian 88% 
Native American 1% 
Pacific Islander 1% 
Other 6% 
Annual Household Income  
< $24,999 27% 
$25,000 - $49,999 18% 
$50,000 - $74,999 16% 
$75,000 - $99,999 3% 
> $100,000 18% 
Prefer to not respond 18% 
Country of Residence  
United States 98% 
Canada 1% 
Other 1% 
Education Level  
High School/GED Less 22% 
Trade School 6% 
Some College 23% 
Bachelor’s Degree 32% 
Graduate Degree  17% 
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BAI Results 
 The overall median score for BAI was 8 (IQR 3-14) with no statistical significant 
differences between the median score between men and women (Table 2). Comparisons of the 
BAI scores for the individual BAI items and compared across stratifications by intellectual 
disability, education, and TSC disease severity. The p-values were controlled for Type I errors 
and are presented in Table 3A. Nearly all of the BAI items, excluding unsteadiness, hands 
trembling, feelings of choking, and face flushed, showed a statistically significant relationship 
demonstrating more severe symptoms of anxiety in individuals who self-reported higher levels 
of TSC disease severity.  Similarly, the majority of BAI components, with the exception of 
feeling hot, feelings of choking, hands trembling, face flushed, and sweating (not due to heat), 
showed a statistically significant trend in which individuals with intellectual disabilities who 
have TSC indicated more severe anxiety related symptoms. Additionally, respondents with 
some level of higher education indicated a statistically significant increase in severity of 
anxiety related symptoms including feelings of choking, terrified, fear of losing control, 
feeling faint, wobbliness, feeling dizzy or lightheaded, and difficulty breathing. There was no 
significant correlation between intellectual disability and education level. 
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Table 2: BAI, BDI-II, and Brief-IPQ Scores 
 Median (25th-75th) 
BAI 8 (3 – 14) 
Women 7 (3 – 11) 
Men 10.5 (4 – 17) 
BDI-II 8 (2 – 20.5) 
Women 7 (2 – 16)* 
Men 22 (6 – 26)* 
Brief-IPQ 45.5 (35.5 – 53.5) 
Women 45 (35 – 54) 
Men 47 (40 – 53) 
 
Table 3A: BAI Item Analysis Intellectual  
Disability 
Education  
Level 
Disease 
 Severity 
Numbness or tingling 0.001 0.552 0.017 
Feeling Hot 0.302 0.496 0.015 
Wobbliness in legs 0.001 0.036 0.005 
Unable to relax 0.021 0.192 0.016 
Fear of the worst happening 0.002 0.187 0.005 
Dizzy or lightheaded 0.001 0.049 0.013 
Heart Pounding or racing 0.022 0.120 0.237 
Unsteady 0.000 0.099 0.002 
Terrified 0.004 0.009 0.002 
Nervous 0.001 0.169 0.000 
Feelings of choking 0.228 0.088 0.140 
Hands trembling 0.260 0.323 0.506 
Shaky 0.000 0.687 0.002 
Fear of losing control 0.001 0.013 0.003 
Difficulty breathing 0.007 0.036 0.000 
Fear of dying 0.001 0.301 0.001 
Scared 0.003 0.062 0.000 
Indigestion/discomfort in abdomen 0.025 0.127 0.003 
Faint 0.000 0.036 0.000 
Face flushed 0.074 0.190 0.213 
Sweating (not due to heat) 0.274 0.193 0.007 
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BDI-II and Brief-IPQ Results 
 The overall median score for BDI-II was 8 (IQR 2-20.5; Table 2). The difference 
between the median BDI-II score for men and women was statistically significant with men 
scoring higher than the females (p = 0.023; Table 2). Comparisons of the BDI-II scores for the 
individual BDI-II items were compared across stratifications by intellectual disability, 
education, and TSC disease severity. The p-values were controlled for Type I errors and 
presented in Table 3B. Slightly fewer than half of the BDI-II items (9 out of 21), including 
sadness, pessimism, suicidal thoughts or wishes, indecisiveness, worthlessness, change in 
appetite, difficulty concentrating, and loss of interest in sex, showed a statistically significant 
relationship demonstrating more severe symptoms in individuals who self-reported higher 
levels of TSC disease severity.  Individuals with a diagnosis of intellectual disability 
demonstrated a statistically significant increase in severity of depression symptoms, including 
the BDI-II items of sadness, pessimism, indecisiveness, loss of energy, change in appetite, 
difficulty concentrating, and tiredness. Similarly, respondents with some level of higher 
education illustrated a statistically significant increase in the BDI-II items of self-dislike and 
worthlessness. There was no significant correlation between intellectual disability and 
education level. The overall median for the Brief-IPQ was 45.5 (IQR 35.5 - 53.5) with no 
statistically significant differences between men and women (Table 2). 
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Table 3B: BDI-II Item Analysis Intellectual 
Disability 
Education 
Level 
Disease 
Severity 
Sadness 0.001 0.269 0.002 
Pessimism 0.043 0.342 0.004 
Past Failure 0.361 0.131 0.295 
Loss of Pleasure 0.178 0.134 0.284 
Guilty Feelings 0.086 0.824 0.128 
Punishment 0.986 0.190 0.493 
Self-Dislike 0.148 0.026 0.465 
Self-Criticalness 0.332 0.103 0.405 
Suicidal Thoughts or Wishes 0.313 0.424 0.005 
Crying 0.551 0.409 0.135 
Agitation 0.112 0.129 0.032 
Lost of Interest 0.659 0.387 0.147 
Indecisiveness 0.004 0.533 0.001 
Worthlessness 0.127 0.047 0.021 
Loss of Energy 0.038 0.164 0.064 
Change in Sleeping Pattern 0.085 0.436 0.211 
Irritability 0.187 0.189 0.056 
Change in Appetite 0.014 0.495 0.003 
Difficulty in Concentrating 0.033 0.408 0.008 
Tiredness or Fatigue 0.002 0.471 0.073 
Loss of Interest in Sex 0.110 0.769 0.015 
 
Barriers and Utilization of Mental Health Services 
Out of 69 respondents, 57% (n = 39) reported receiving mental health treatment at 
some point over their lifetime. Of the group of individuals with a history of receiving mental 
health treatment, approximately 31% (n = 12) of them had not seen a mental health specialist 
in the past year. In contrast, 56% (n = 22) of respondents from the treatment group reported 
seeing a mental health specialist on a regular basis. Of these respondents who were receiving 
mental health services, the majority of respondents either “strongly agreed” or “agreed” that 
mental health treatment was meeting their needs (65%, n = 25) as well as improving their 
overall mental health (74%, n = 29).  From the group of individuals who had never previously 
received mental health treatment (n = 30), 23% of them felt they had symptoms that could be 
addressed by a mental health specialist and 67% of them either “strongly agreed” or “agreed” 
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that they would feel comfortable asking their primary provider about mental health services.  
The treatment group and the non-treatment group’s responses to stigma and cost as being 
barriers to accessing mental health resources are shown in Figure 2. In regards to barriers to 
accessing mental health services, about half of the individuals from the mental health treatment 
group (n = 39, 51%) felt that cost would prevent continued use of services while only a fifth 
(n=33, 21%) of the individuals from that group felt that stigma would prevent continued use of 
services.  Of the group of individuals with no previous use of mental health services, 27% (n = 
8) of individuals felt cost would prevent initiating mental health treatment while 20% (n = 6) 
of individuals felt that stigma would prevent initiating mental health treatment. There was no 
statistically significant relationship between stigma and socioeconomic status (SES) as well as 
cost and SES as a function of income, occupation or education.  
Figure 2: Cost versus Stigma as Barriers to Accessing Mental Health Services 
 
Figure 2 illustrates that cost was overall a more significant barrier to accessing mental health 
resources in comparison to stigma. Positive values were indicative of cost being a more 
prominent barrier than stigma and negative values were indicative of stigma being a more 
prominent barrier than cost. The value of zero represents that the respondent felt stigma and cost 
were equal barriers. 
15 
DISCUSSION 
 The study described here set out to evaluate perception of disease severity within the 
adult TSC population. Overall, men and women both indicated a perception of moderate 
disease severity. The Brief-IPQ outcome supports the medical community’s understanding of 
the clinical features of TSC. The implication of a moderate level of disease severity stems 
from the spectrum of symptoms and life-long nature of the condition that contributes to 
feelings of little personal control over the disease. The results of our study bring attention to 
the individual’s daily experiences with their disease, regardless of the medical provider’s 
perception of their patient’s disease severity. Medical providers, as well as members of the 
TSC community, could benefit from studies that develop evidence-based care guidelines 
regarding the psychosocial impact of TSC in an effort to tailor and improve overall clinical 
care.  
 Our study results showed a moderate association between one’s perception of disease 
severity and self-reported depression and anxiety. There was a strong correlation between BAI 
and BDI-II scores. Even though these tools were designed with the intent of discriminant 
validity, previous studies have also indicated moderate to strong correlations between the BAI 
and BDI-II (21, 25).  Suggested explanations for this phenomenon include that depression and 
anxiety often co-occur or that depression and anxiety are simply different points on the same 
spectrum (26, 27). The correlation seen in our study further supports their interrelated nature 
given that the BAI and BDI-II tools were developed to be complementary to each other. The 
overall BAI and BDI-II scores of our study population correspond and build upon previous 
neuropsychiatric co-morbidity studies that indicate that the chronic illness populations have 
increased incidences of anxiety and depression (28-33).  
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 The analysis of each validated measure indicated a significant difference in the median 
BDI-II score between men and women. Our results do not align with the previously 
established trend of women typically having higher BDI-II scores in comparison to men, as 
well as the general consensus that women are twice as likely to experience depression (34, 35). 
The increased incidence of depression within the TSC community compared to the general 
population is well known, but there has not been any previous evidence of men with TSC more 
frequently experiencing depression than women with TSC. It is possible that the men in our 
study feel more disenfranchised by their diagnosis and severity of TSC in comparison to the 
women leading to heightened levels of depression. The literature regarding depression in men 
has been growing in recent years. Current theories thought to contribute to depression in men 
include difficulty in fulfilling gender roles, biological factors, and/or coping styles (36). 
Furthermore, it has been determined that men demonstrate a wider range of depressive 
symptoms that stray from the traditionally known symptoms; therefore, typical methods used 
to diagnose depression could lead to under-diagnosis (37). Given the moderate level of 
depression among the men in our study, it would be beneficial to further delve into the 
etiology and risk factors that contribute to depression in men with TSC as well as in men with 
other chronic illnesses.  
 There was no significant difference between the median BAI scores for men and 
women with both sexes falling in the minimal to mild range of anxiety. Despite the lack of 
significance, the trend of women scoring on average four points higher on the scale (as 
outlined in the BAI manual) was not observed in our study population (22).  Comparisons of 
BAI and BDI-II items across stratifications, including intellectual disability, educational level, 
and self-reported perception of disease severity, shed light on specific dimensions that showed 
significant associations in our study. Given the exploratory nature, our results on these 
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variables should primarily offer guidance and tailoring options during clinical interactions with 
patients. Further analysis of these variables on a larger scale would be needed to elucidate a 
more definitive relationship between individual dimensions from the BAI and BDI-II and 
demographic information. Any studies that can provide the medical community insight about 
the complex impact of psychiatric conditions in individuals with a chronic illnesses will 
augment quality of care in the clinical setting. 
 There are several limitations to our study design and the results. The response rate and 
sample size were low, making it difficult to generalize the conclusions from the study to the 
entire TSC community. There is likely a selection bias given that our study sample was 
derived from English-speaking individuals on the TS Alliance listserv with Internet access or 
those who receive their medical care at the University of Texas Health Science Center at 
Houston. Another selection bias is the inclusion criteria requiring that the individual with TSC 
must independently complete the survey. The independence required to complete the survey 
inherently discourages individuals that are cognitively impaired or have more severe 
phenotypes from participating in our survey. Lastly, our survey was conducted through an 
anonymous online survey; therefore, any clinical information gathered during data collection 
was unable to be confirmed by the researchers. Future research regarding how to appropriately 
address the neuropsychiatric phenotype in the clinical setting should be conducted in order to 
effectively change clinical management for these patients. Research opportunities, such as 
evaluating the efficiency and usefulness of an annual visit with a genetic counselor to discuss 
the TAND, will provide the evidence needed to improve the clinical outcomes for patients 
with TSC. 
 Our study results further supports the mental health treatment gap seen in previous 
studies in the TSC community (12, 38). In a recent quality of life study, adults and children 
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with TSC were identified to have significantly reduced quality of life in comparison to the 
general population (39). Regardless of clinical care setting, our data suggest that the majority 
of participants visited at least one medical provider each year. It is imperative for all medical 
disciplines to routinely inquire about physical health changes in addition to changes in the 
patient’s mental health during each clinical evaluation through the use of the TAND checklist. 
In 2004 and 2005, the World Health Organization (WHO) published reports expressing that 
mental health is intricately linked to physical health and is integral to one’s overall well-being 
(40, 41). Specifically, quality of life consists of one’s well-being and life-satisfaction as well 
as the ability to sufficiently function within society (42). Therefore, in order to support 
individuals with TSC in reaching and maintaining optimal quality of life, providers must 
continually assess their mental health from childhood to adulthood. Through appropriate 
referrals and utilization of mental health treatment, individuals can obtain services that can 
lessen disease burden, and in turn, improve quality of life. The burden of mental health 
illnesses was further supported by the 2010 Global Burden Disease Study that highlighted the 
worldwide impact of mental and substance use disorders, as they account for 7.4% of 
disability-adjusted life years (DALYs1) worldwide (43). Within mental and substance use 
disorders, depressive disorders and anxiety disorders accounted for over half of DALYs 
making them the most prominent mental health illnesses worldwide (44). Likewise, the most 
commonly reported neuropsychiatric manifestations in the pediatric and adult TSC population 
are cognitive concerns, depression, and anxiety (38). Our data support previous studies that 
have found individuals who receive mental health treatment report feeling that it does 
																																																													
1		Disability-adjusted life years (DALYs) reflect the overall burden of disease, which corresponds to the number 
of years lost to disability, illness, or premature death. The loss of the equivalent of one year of full health equates 
one DALY (42). 
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improves their overall mental health (15, 16, 45). Furthermore, our results indicate that the 
majority of individuals with TSC would feel comfortable asking their primary provider about 
mental health resources and services; therefore, TSC patients would welcome integrating 
routine mental health evaluations in each clinical interaction.  
 Given the general complexity of accessing mental health services, our study set out to 
identify potential barriers to access specifically in the TSC community. The stigma of mental 
health illnesses and cost of services are commonly known as attitudinal and structural barriers 
to accessing mental health treatment. Interestingly, our study results indicated that stigma was 
not considered a significant barrier to initiating or continuing to access mental health 
resources.  Our results relate and build upon a recent study conducted by Whitley et al, 2014. 
The results of their study identified that individuals with mental health illnesses frequently 
employ behavioral and psychological strategies to prevent or reduce problems associated with 
stigma (46). Moreover, the view of mental health illnesses has evolved to be analogous with 
physical illness (46). If society’s view of mental health continues to shift in a more accepting 
and supportive direction, then stigma will diminish further and will progressively become less 
of a barrier to mental health services (47). In regards to cost, the results of our study align with 
the notion that cost is a persistent and increasing barrier among these individuals.  With 
increasing use of mental health services in conjunction with limited solutions to the issue of 
cost or insurance coverage, individuals will continue to face barriers during utilization of these 
resources (48-50).  
 In conclusion, disease severity had a moderate and low-moderate association with 
anxiety and depression, respectively. Regardless of past utilization, respondents had a positive 
outlook towards the use of mental health services with the major barrier being cost. All 
healthcare providers seeing patients with TSC should use the readily available TAND 
20 
checklist. Specifically, the evaluation for neurobehavioral changes falls within the clinical 
genetic counselor’s scope of practice. For the benefit of the TSC community, a genetic 
counselor could undertake the responsibility of consistently assessing patients with TSC for 
changes or new developments within the spectrum of TAND and subsequently refer any 
patients in need of mental health services.  
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